Vilaça Marta, Braga Fátima, Mesquita Alexandra
Oncology, Hospital Pedro Hispano, Matosinhos, PRT.
Cureus. 2022 Mar 29;14(3):e23598. doi: 10.7759/cureus.23598. eCollection 2022 Mar.
The treatment landscape of metastatic renal cell carcinoma (mRCC) has changed in the last decade with improvements in overall survival. Overall survival ranges from 57 months in good-to-intermediate prognosis patients to 19 months in poor prognosis patients. The most frequent sites of metastasis are the lungs, bone, distant lymph nodes, liver, adrenal, and brain. Cutaneous metastases are rare and represent an end-stage disease with a worse prognosis. Studying long-term survivors of mRCC can help clinicians to identify potential predictors of response to targeted therapy and define the best treatment sequences in this setting. In this case, we report a 59-year-old man with a good mRCC prognosis who is alive 156 months after the diagnosis of mRCC, 108 months with cutaneous metastases. The patient underwent five treatment lines, with good tolerance and quality of life. This therapeutic sequence was based on new treatment options and new evidence concerning mRCC.
在过去十年中，随着总体生存率的提高，转移性肾细胞癌（mRCC）的治疗格局发生了变化。总体生存时间从预后良好至中等的患者的57个月到预后较差的患者的19个月不等。最常见的转移部位是肺、骨、远处淋巴结、肝、肾上腺和脑。皮肤转移罕见，代表终末期疾病，预后更差。研究mRCC的长期幸存者有助于临床医生识别对靶向治疗反应的潜在预测因素，并确定在这种情况下的最佳治疗顺序。在此病例中，我们报告一名mRCC预后良好的59岁男性，在诊断为mRCC后存活了156个月，出现皮肤转移后存活了108个月。该患者接受了五条治疗线的治疗，耐受性良好，生活质量较高。这种治疗顺序基于mRCC的新治疗选择和新证据。
